<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140580</url>
  </required_header>
  <id_info>
    <org_study_id>4.3, 6th June 2013</org_study_id>
    <nct_id>NCT02140580</nct_id>
  </id_info>
  <brief_title>OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP</brief_title>
  <acronym>OPTIMIST-A</acronym>
  <official_title>Multicentre Randomised Controlled Trial of Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on Continuous Positive Airways Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menzies Institute for Medical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Hobart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Women's Hospital, Melbourne, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NorthShore University HealthSystem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monash Medical Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mercy Hospital for Women, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Auckland City Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Middlemore Hospital, New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zekai Tahir Burak Women's Health Research and Education Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kapiolani Medical Center For Women &amp; Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cooper Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West Virginia University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uludag University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziv Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bnai Zion Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dunedin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kanuni Sultan Suleyman Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Menzies Institute for Medical Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial question: Does administration of exogenous surfactant using a minimally-invasive
      technique improve outcome in preterm infants 25-28 weeks gestation treated with continuous
      positive airway pressure (CPAP)? Trial hypothesis: That early surfactant administration via a
      minimally-invasive technique to preterm infants on CPAP will result in a lesser duration of
      mechanical respiratory support, and a higher incidence of survival without bronchopulmonary
      dysplasia. Trial design: Multicentre, randomised, masked, controlled trial in inborn preterm
      infants 25-28 weeks gestation, aged less than 6 hours, requiring CPAP because of respiratory
      distress, with an FiO2 of &gt;=0.3 and CPAP pressure 5-8. Infants randomised to surfactant
      treatment receive 200 mg/kg of poractant alfa (Curosurf) administered under direct
      laryngoscopy using a surfactant instillation catheter, followed by reinstitution of CPAP.
      Controls continue on CPAP. The intervention is masked from the clinical team. Care thereafter
      is as per usual in both groups, other than the requirement to adhere to intubation criteria.
      The primary outcome is incidence of death or BPD. Secondary outcomes include incidence of
      death, major neonatal morbidities (BPD, intraventricular haemorrhage, periventricular
      leukomalacia, retinopathy of prematurity, necrotising enterocolitis), pneumothorax and patent
      ductus arteriosus; need for intubation and surfactant therapy; durations of mechanical
      respiratory support, intubation, CPAP, intubation and CPAP, high flow nasal cannula (HFNC),
      oxygen therapy, intensive care stay and hospitalisation; hospitalisation cost; applicability
      and safety of the MIST procedure; and outcome at 2 years. The sample size is 303/group,
      allowing detection of a 33% difference in the primary outcome with 90% power. The trial
      commenced at Royal Hobart Hospital December 2011 and Royal Women's Hospital during 2012, and
      will ultimately be conducted over 5 years in multiple centres internationally.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. OPTIMIST-A TRIAL SUMMARY RESEARCH QUESTION Does administration of exogenous surfactant
      using a minimally-invasive technique improve outcome in preterm infants 25-28 weeks gestation
      treated with continuous positive airway pressure (CPAP)?

      BACKGROUND Nasal CPAP is often very effective in preterm infants as the initial means of
      respiratory support, but a sub-group of infants, most with features of respiratory distress
      syndrome, fail on CPAP and require intubation and ventilation in the first 72 hours. When
      compared to those in whom CPAP is successful, infants failing CPAP have a substantially
      longer duration of respiratory support, and a higher risk of adverse outcomes. Decreasing the
      risk of CPAP failure would thus seem advantageous, and may be achievable with minimally
      invasive surfactant therapy (MIST), in which surfactant is administered to a spontaneously
      breathing infant who then remains on CPAP. A technique of MIST (the &quot;Hobart method&quot;) using a
      semi-rigid surfactant instillation catheter has been shown to be feasible in preterm infants
      on CPAP, and appears to have the potential to alter respiratory course and outcome. This
      method of MIST now requires evaluation in randomised controlled trials.

      RESEARCH DESIGN Multicentre, randomised, masked, controlled trial.

      RECRUITMENT Entry criteria Inborn preterm infants 25-28 weeks gestation, aged less than 6
      hours, who were not intubated at birth but require CPAP or NIPPV because of respiratory
      distress, with a CPAP pressure of 5-8 cm H2O and FiO2 ≥0.30.

      Exclusion criteria Infants will be excluded if in imminent need of intubation, or if there is
      a congenital anomaly or alternative cause for respiratory distress.

      RANDOMISATION With parental consent, eligible infants will be randomly allocated using a
      web-based randomisation server, with stratification by study centre, to receive exogenous
      surfactant via the Hobart MIST technique, or to continue on CPAP.

      INTERVENTION Infants randomised to surfactant treatment will receive a dose of poractant alfa
      (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter,
      at a dosage of 200 mg/kg. CPAP will thereafter be reinstituted. Controls will continue on
      CPAP. The intervention will be masked from the clinical team.

      POST-INTERVENTION MANAGEMENT Other than the requirement to adhere to intubation criteria in
      the first week, and in some cases perform a room air trial at 36 weeks corrected gestation,
      management after intervention will be at the discretion of the clinical team. Titration of
      CPAP pressure is encouraged, with a permitted maximum of 8 cm H2O. Nasal IPPV (bi-level CPAP)
      is allowable. Early caffeine therapy is expected.

      Criteria for intubation: Enrolled infants on CPAP will be intubated if FiO2 ≥0.45, or if
      there is unremitting apnoea or persistent acidosis. These criteria apply during the first
      week of life, and to the first episode of intubation only.

      FOLLOWUP: At 2 years corrected age, parents of each infant will complete a brief health
      assessment and a validated child development assessment (PARCA-R, Dev Med Child Neurol
      2004;46:389-97) administered as a web-based questionnaire located on a secure server. The
      infant-specific link to the questionnaire, and reminders where necessary, will be sent
      electronically to the parents by research personnel at each Site, thus maintaining
      confidentiality. No identifying details will be revealed in the completion of the
      questionnaire.

      OUTCOMES Primary outcome: Incidence of composite outcome of death or physiological
      bronchopulmonary dysplasia (BPD).

      Secondary outcomes: Incidence of death, major neonatal morbidities (BPD, intraventricular
      haemorrhage, periventricular leukomalacia, retinopathy of prematurity, necrotising
      enterocolitis), pneumothorax and patent ductus arteriosus; need for intubation and surfactant
      therapy; durations of mechanical respiratory support, intubation, CPAP, intubation and CPAP,
      high flow nasal cannula (HFNC), oxygen therapy, intensive care stay and hospitalisation;
      hospitalisation cost; applicability and safety of the MIST procedure; and outcome at 2 years.

      SAMPLE SIZE 606 infants (303 per group), giving 90% power to detect a 33% reduction in death
      or BPD from the anticipated rate of 38% in the control arm, α = 0.05.

      TRIAL PLAN The OPTIMIST trials will commence at RHH Hobart and RWH Melbourne during 2011. All
      Australasian neonatal units, and selected international centres including those in the
      Vermont- Oxford Network, will be invited to join the trials. A full complement of
      participating centres is expected by early 2014. Recruitment will thereafter proceed at full
      rate until completion, which is estimated to take up to 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or physiological bronchopulmonary dysplasia</measure>
    <time_frame>36 weeks post menstrual age</time_frame>
    <description>Composite outcome of death by 36 weeks or physiological bronchopulmonary dysplasia (BPD). Physiological BPD is assessed at 36 weeks post-menstrual age, and is defined as either need for respiratory support (intubation / CPAP / high flow nasal cannula &gt; 2 L/min) or need for FiO2 &gt;=0.3 or failure of a room air trial conducted at 36 weeks post-menstrual age. This will be assessed by the research nurse at each centre.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>36 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major morbidity</measure>
    <time_frame>36 weeks post menstrual age</time_frame>
    <description>Major morbidity, defined as one or more of BPD, grade III or IV intraventricular haemorrhage, periventricular leukomalacia or retinopathy of prematurity &gt; stage 2, occurring at any time up to 36 weeks post menstrual age. Screening for intraventricular haemorrhage, periventricular leukomalacia and retinopathy of prematurity will be performed as routine care, and the results taken from the medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumothorax</measure>
    <time_frame>36 weeks post menstrual age</time_frame>
    <description>Pneumothorax at any time up to 36 weeks post menstrual age, as documented in medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of respiratory support</measure>
    <time_frame>During first hospitalisation (average assessment period 14 weeks)</time_frame>
    <description>Duration of respiratory support, defined as cumulative hours of all episodes of intubation, nasal CPAP and high flow nasal cannula oxygen (flow rate &gt;= 2 litres/min). This information will be derived from medical record or unit database.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary dysplasia</measure>
    <time_frame>36 weeks post menstrual age</time_frame>
    <description>Bronchopulmonary dysplasia (BPD) will be assessed both clinically (need for mechanical respiratory support and/or an oxygen requirement at 36 weeks corrected gestation), and by a physiological definition. Physiological BPD is assessed at 36 weeks post-menstrual age, and is defined as either need for respiratory support (intubation / CPAP / high flow nasal cannula &gt; 2 L/min) or need for FiO2 &gt;=0.3 or failure of a room air trial conducted at 36 weeks post-menstrual age. This will be assessed by the research nurse at each centre.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of bradycardia and hypoxaemia during intervention</measure>
    <time_frame>During intervention</time_frame>
    <description>Heart rate and oxygen saturation will be monitored continuously during the intervention. The severity and duration of bradycardia and hypoxia will thus be documented during delivery of exogenous surfactant via brief tracheal catheterisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discomfort during intervention</measure>
    <time_frame>During intervention</time_frame>
    <description>The incidence of apparent discomfort, as judged by the nurse assisting in the surfactant delivery procedure, will be ascertained in the group randomised to receive surfactant via brief tracheal catheterisation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospitalisation cost</measure>
    <time_frame>First hospitalisation (average assessment period 14 weeks)</time_frame>
    <description>The mean of patient billings and mean cost of hospitalisation per patient will be determined, and compared between groups.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">606</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>Minimally invasive surfactant therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minimally invasive surfactant therapy - delivery of exogenous surfactant to the lung via brief catheterisation of the trachea with an instillation catheter in a preterm infant who is being supported with continuous positive airway pressure (CPAP) via nasal prongs or mask. Poractant alfa (Curosurf) at a dosage of 200 mg/kg will be administered over 15 - 30 seconds. Total duration of the procedure will be less than 5 minutes, followed by reinstitution of CPAP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuation on CPAP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Standard control treatment. After randomisation, infants will receive a sham treatment from a treatment team not engaged in clinical care. This will not involve removal of prongs or discontinuation of CPAP but will require setting up intubation equipment, screening the baby, testing suction unit, repositioning of the baby and changing the baby's monitoring. CPAP will thereafter continue.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Minimally invasive surfactant therapy</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Minimally invasive surfactant therapy</arm_group_label>
    <other_name>16G Angiocath, Product No. 382259, BD, Sandy, UT, USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Continuation on CPAP</intervention_name>
    <description>Sham Comparator</description>
    <arm_group_label>Continuation on CPAP</arm_group_label>
    <other_name>Standard care - continuation of CPAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age 25-28 completed weeks

          -  Requiring CPAP or non-invasive positive pressure ventilation with signs of early
             respiratory distress.

          -  CPAP pressure of 5-8 cm H2O and FiO2 &gt;=0.30.

          -  Less than 6 hours of age.

          -  Agreement of the Treating Physician in charge of the infant's care.

          -  Signed parental consent.

        Exclusion Criteria:

          -  Previously intubated, or in imminent need of intubation

          -  Congenital anomaly or condition that might adversely affect breathing.

          -  Identifiable alternative cause for respiratory distress (e.g. congenital pneumonia or
             pulmonary hypoplasia).

          -  Lack of availability of an OPTIMIST treatment team.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Dargaville, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Menzies Institute of Medical Research, University of Tasmania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Dargaville, MD</last_name>
    <phone>+61 361668308</phone>
    <email>peter.dargaville@ths.tas.gov.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Butterley, MN</last_name>
    <phone>+61 3 61668266</phone>
    <email>optimist.trials@menzies.utas.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale-New Haven Children's Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Ehrenkranz, MD</last_name>
      <email>richard.ehrenkranz@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Ehrenkranz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kapi'olani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheree Kuo, MD</last_name>
      <email>Shereek@kapiolani.org</email>
    </contact>
    <contact_backup>
      <last_name>Micah Tong, CCRP</last_name>
      <phone>(808) 983-6427</phone>
      <email>micah.tong@hawaiipacifichealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sheree Kuo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Neal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Venkataraman Balaraman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore Health University HealthSystem Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Derrick, MD</last_name>
      <phone>847-570-2045</phone>
      <email>MDerrick@northshore.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Derrick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alla Kushnir, MD</last_name>
      <email>kushnir-alla@CooperHealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Camparri, RN</last_name>
      <email>Camparri-heather@cooperhealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>All Kushnir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Polak, MD</last_name>
      <email>mpolak@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Polak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Dargaville, MD</last_name>
      <phone>+61 3 61668308</phone>
      <email>peter.dargaville@ths.tas.gov.au</email>
    </contact>
    <investigator>
      <last_name>Tony DePaoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Womens Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omar Kamlin, MD</last_name>
      <phone>+61 3 83453769</phone>
      <email>omar.kamlin@thewomens.org.au</email>
    </contact>
    <investigator>
      <last_name>Omar Kamlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital for Women</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajit Aiyappan, MD</last_name>
      <phone>+61 3 8458 4736</phone>
      <email>AAiyappan@mercy.com.au</email>
    </contact>
    <investigator>
      <last_name>Ajit Aiyappan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Tan, MD</last_name>
      <phone>+61 3 9594 6666</phone>
      <email>Kenneth.Tan@southernhealth.org.au</email>
    </contact>
    <investigator>
      <last_name>Kenneth Tan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bader, MD</last_name>
      <email>davidbade@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Bader, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziv Medical Center</name>
      <address>
        <city>Tsefat</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Shinwell, MD</last_name>
      <email>Eric.s@ziv.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Eric Shinwell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariam Buksh, MB BS</last_name>
      <phone>+64 9 375 4300</phone>
      <email>MariamB@adhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Mariam Buksh, MB BS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1640</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Mildenhall, MD</last_name>
      <phone>+6421784022</phone>
      <email>Lindsay.Mildenhall@middlemore.co.nz</email>
    </contact>
    <investigator>
      <last_name>Lindsay Mildenhall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center, Ljubljana</name>
      <address>
        <city>Zaloska</city>
        <state>Ljubljana</state>
        <zip>SI-1525</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilijana Kornhauser-Cerar, MD</last_name>
      <email>lilijanakornhauser-cerar@guest.arnes.si</email>
    </contact>
    <investigator>
      <last_name>Lilijana Kornhauser-Caerar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uludag University Hospital</name>
      <address>
        <city>Gorukle</city>
        <state>Bursa</state>
        <zip>16120</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merih Cetinkaya, MD</last_name>
      <email>drmerih@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Merih Cetinkaya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zekai Tahir Burak Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gozde Kanmaz Kutman, MD</last_name>
      <phone>+90 505 5881189</phone>
      <email>gzdekanmaz@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Fadik Gokelek, RN</last_name>
      <email>f.kulaksiz@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gozde Kanmaz Kutman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Israel</country>
    <country>New Zealand</country>
    <country>Slovenia</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dargaville PA, Aiyappan A, De Paoli AG, Kuschel CA, Kamlin CO, Carlin JB, Davis PG. Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure. Arch Dis Child Fetal Neonatal Ed. 2013 Mar;98(2):F122-6. doi: 10.1136/archdischild-2011-301314. Epub 2012 Jun 9.</citation>
    <PMID>22684154</PMID>
  </reference>
  <reference>
    <citation>Dargaville PA, Aiyappan A, Cornelius A, Williams C, De Paoli AG. Preliminary evaluation of a new technique of minimally invasive surfactant therapy. Arch Dis Child Fetal Neonatal Ed. 2011 Jul;96(4):F243-8. doi: 10.1136/adc.2010.192518. Epub 2010 Oct 21.</citation>
    <PMID>20971722</PMID>
  </reference>
  <reference>
    <citation>Dargaville PA. Innovation in surfactant therapy I: surfactant lavage and surfactant administration by fluid bolus using minimally invasive techniques. Neonatology. 2012;101(4):326-36. doi: 10.1159/000337346. Epub 2012 Jun 1. Review.</citation>
    <PMID>22940622</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>July 5, 2016</last_update_submitted>
  <last_update_submitted_qc>July 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menzies Institute for Medical Research</investigator_affiliation>
    <investigator_full_name>Professor Peter Dargaville</investigator_full_name>
    <investigator_title>Consultant Neonatologist, Paediatric and Neonatal Intensive Care Unit, Royal Hobart Hospital</investigator_title>
  </responsible_party>
  <keyword>Minimally-invasive surfactant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

